Mealey's (October 7, 2022, 12:03 PM EDT) -- WASHINGTON, D.C. — Novartis Pharmaceuticals Corp. is not entitled to the stay of a Federal Circuit U.S. Court of Appeals mandate that held a patent for multiple sclerosis (MS) treatment to be invalid, a generic drugmaker tells the U.S. Supreme Court in an opposition brief, arguing that the appeals court correctly found that the patent in suit did not contain the primary limitation in its written description....